CSF3 and myelodysplastic syndrome: During the follow up period (Table 3), Neutp MDS patients were treated with significantly more G-CSF (40% vs. 12%, p = 0.003) and red blood cell (RBC) transfusions (54% vs. 32%, p = 0.043), but not erythroid stimulating agents (ESAs, 48% vs. 43%, p = 0.69).